CC BY-NC-ND 4.0 · Avicenna J Med 2015; 05(01): 6-10
DOI: 10.4103/2231-0770.148501

Association of microalbuminuria with ischemic heart disease in non-diabetic Asian-Indians: A case control study

Sowjanya Naha
Department of Medicine, Kasturba Hospital, Manipal, Karnataka, India
Kushal Naha
Department of Medicine, Kasturba Hospital, Manipal, Karnataka, India
Vinay R Pandit
Department of Medicine, Kasturba Hospital, Manipal, Karnataka, India
R Balasubramanian
Department of Medicine, Indira Gandhi Medical College and Research Institute, Puducherry, India
› Author Affiliations


Context: Microalbuminuria is a known indicator of atherosclerosis and its association with ischemic heart disease (IHD) has been extensively studied in the diabetic population. The significance of urine microalbumin in non-diabetics, however, is yet to be elucidated. Aim: To determine whether an independent association exists between microalbuminuria and IHD in non-diabetic Asian-Indians, and the level of microalbuminuria predictive of concomitant IHD. Materials and Methods: A cross-sectional case-control study was conducted between July 2009 and June 2011. Non-diabetic patients undergoing evaluation for IHD were divided into cases and controls, based on the presence or absence of IHD, respectively. Fifty cases and 50 controls were included, and matched by age, sex, smoking habit, hypertension and body-mass index (BMI). Fasting blood glucose (FBG), fasting lipid profile, and urine microalbumin were recorded for all patients. Results: Mean fasting glucose, mean low density lipoprotein (LDL)-cholesterol and mean urine microalbumin were all significantly higher in cases compared to controls. Urine microalbumin was independently associated with IHD, and microalbumin greater than 12.6 mg/g was predictive of IHD (OR: 13.5; 95% CI, 4.6-39.9; P < 0.001). Conclusion: Urine microalbumin is independently associated with IHD in non-diabetics and levels greater than 12.6 mg/g are predictive of IHD.

Publication History

Article published online:
09 August 2021

© 2015. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

  • References

  • 1 World Health Organization (WHO). Cardiovascular diseases, fact sheet number 317 [Internet]. Geneva, Switzerland: WHO; 2013, Available from:[Last updated in 2013 Mar; ?Last accessed in 2013 Mar 31].
  • 2 Alwan A, Maclean DR, Riley LM, d′Espaignet ET, Mathers CD, Stevens GA, et al. Monitoring and surveillance of chronic non-communicable diseases: Progress and capacity in high-burden countries. Lancet 2010;376:1861-8.
  • 3 Alwan A, Armstrong T, Cowan M, Riley L. Noncommunicable diseases country profiles 2011 [Internet]. 2011. Available from: [Last accessed in 2013 Mar 31].
  • 4 Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010;35:72-115.
  • 5 Smith SC Jr. Reducing the global burden of ischemic heart disease and stroke: A challenge for the cardiovascular community and the United Nations. Circulation 2011;124:278-9.
  • 6 Koenig W. Cardiovascular biomarkers: Added value with an integrated approach? Circulation 2007;116:3-5.
  • 7 Garg JP, Bakris GL. Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43.
  • 8 American Diabetes Association. Standards of medical care in diabetes--2006. Diabetes Care 2006;29 Suppl 1:S4-42.
  • 9 de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 2006;17:2120-6.
  • 10 Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006;113:2335-62.
  • 11 Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007;2:581-90.
  • 12 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36 Suppl 1:S67-74.
  • 13 Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, et al. PREVEND IT Study Group. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther 2006;28:432-44.
  • 14 Hashim R, Nisar S, Khalil ur Rehman, Naqi N. Microalbuminuria: Association with ischaemic heart disease in non-diabetics. J Ayub Med Coll Abbottabad 2006;18:40-3.
  • 15 Awan ZA, Naveed AK, Malik MM, Khan S. Microalbuminuria in angiographically documented coronary heart disease in non-diabetic and normotensive individuals. Ann King Edward Med Univ 2009;15:111-6.
  • 16 Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 2005;112:969-75.
  • 17 Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. PREVEND Study Group. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005;28:2525-30.
  • 18 Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:617-24.
  • 19 Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004;33:189-98.
  • 20 Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7.
  • 21 Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, de Jong PE, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 2000;21:1922-7.